SCHEMBL7526465

SCHEMBL7526465

CCOC(=O)N1CCN(c2ccccc2C=O)CC1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
MAPT P10636 5/20 0.63
ALDH1A1 P00352 4/20 0.63
LMNA P02545 2/20 0.52
KDM4E B2RXH2 2/20 0.52
TSHR P16473 2/20 0.52
NPC1 O15118 1/20 0.52
HPGD P15428 1/20 0.52
ALOX15 P16050 1/20 0.52
MAPK1 P28482 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HSD17B10 Q99714 1/20 0.52
PKM P14618 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7832611 0.89 GAA (0.54) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL6225699 0.87 GAA (0.52) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL114482 0.83 GPR119 (0.53) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL3436308 0.82 MAPT (0.78) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL7224481 0.81 GAA (1.00) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL18914464 0.81 HPGD (0.60) SMN1; SMN2MAPTALDH1A1KDM4ETSHR
SCHEMBL11093641 0.80 GAA (0.72) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL15651250 0.80 GAA (0.72) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL6809615 0.79 CKS1B (0.53) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL8327398 0.79 L3MBTL1 (0.49) ALDH1A1KDM4ETSHRL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020193389-A1 Method of inhibiting neoplastic cells with imidazoquinazoline derivatives OSI PHARMACEUTICALS, INC. 2002-12-19 US disclosed
US-6127541-A 8-((DISUBSTITUTED AMINO)BENZYLAMINO)-2,3-DIHYDRO-1H-IMIDAZO(4,5-G)QUINAZOLINE-(2-THIONE OR 2-ONE); SELECTIVE CYCLIC GUANOSINE 3',5' MONOPHOSPHATE (CGMP)--SPECIFIC PHOSPHODIESTERASE (PDE) INHIBITORY ACTIVITY KYOWA HAKKO KOGYO CO., LTD. (JP) 2000-10-03 US disclosed
CN-1205008-A Imidazoquinazoline derivatives KYOWA HAKKO KOGYO KK (JP) 1999-01-13 CN disclosed
EP-0863144-A1 IMIDAZOQUINAZOLINE DERIVATIVES Kyowa Hakko Co., Ltd. (JP) 1998-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193389-A1 Method of inhibiting neoplastic cells with imidazoquinazoline derivatives MKI67, HRAS, VHL GAA 2633/4885SMN1; SMN2 4177/4885MAPT 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.